A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting

Phase 2

Phase 3

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Sponsor:

Beacon Therapeutics

Code:

NCT04850118

Conditions

X-Linked Retinitis Pigmentosa

Eligibility Criteria

Sex: Male

Age: 12 - 50

Healthy Volunteers: Not accepted

Interventions

rAAV2tYF-GRK1-hRPGRco

Control

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Beacon Therapeutics on 2025-05-18.